Amiens

• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended recruitment
  2022-501966-23-00 5 2018-09-11 Resected High-Risk Stage II Melanoma
• A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended recruitment
  2024-510913-13-00 10 2018-05-18 Previously Untreated Metastatic or Unresectable Melanoma
• A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Ended recruitment
  2023-506429-13-00 5 2018-05-02 Progressive multiple sclerosis (PMS)
• Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, … Ended recruitment
  2024-512470-10-00 11 2018-02-02 End-stage Renal disease
• Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended recruitment
  2024-513964-24-00 5 2017-09-14 Squamous cell carcinoma, previously untreated Stage III, stage IVa (op
• PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended recruitment
  2024-510704-37-00 5 2017-03-22 ER+/HER2- metastatic breast cancer
• Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy Ended recruitment
  2024-513972-16-00 5 2017-01-30 - Resected tumors of sinuses or salivary glands - Non-operable tumors
• An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended recruitment
  2023-505246-26-00 5 2016-01-27 High- or very-high risk, localized or locally advanced prostate cancer
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• Phase III trial of laryngeal preservation comparating chemotherapy followed by radiotherapy to chemotherapy administrated during radiotherap … Ended recruitment
  2024-513976-16-00 5 2015-06-26 squamous cell carcinomas of the larynx or hypopharynx locally advance
• Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients Ended recruitment
  2024-515171-35-00 5 2011-07-06 Prostatic adenocarnicoma with high risk of recurrence
• Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted
  2024-516687-28-00 5 2025-06-06 Patients with GPA and inadequate response to standard of care therapy
• Study of Taxane-Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma … Halted
  2023-510559-41-00 4 2025-01-02 Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
• SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial Ended
  2024-513648-27-00 4 2024-10-25 Patients with newly or active diffuse Systemic sclerosis (SSc) at the
• A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin-X … Ended
  2022-501952-27-00 5 2024-04-19 Hospital-acquired bacterial pneumonia (HABP), including ventilated HAB
• COTRIVAP - Efficacy of cotrimoxazole as a de-escalation treatment of Ventilator-Associated Pneumonia in intensive care unit Ended
  2023-505108-52-00 5 2023-12-20 Intensive Care
• A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) Ended
  2022-502227-22-00 4 2023-10-25 Autoimmune disease
• Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me … Ended
  2022-502372-22-01 4 2023-10-19 Metastatic Breast Cancer HR+, HER2-
• Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (JAKUVEITE) Ended
  2024-513802-77-00 5 2023-08-30 Active non-anterior non-infectious uveitis
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended
  2022-502234-70-00 5 2023-07-14 Chronic Obstructive Pulmonary Disease (COPD)
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 5 2023-06-08 Moderately to severely active ulcerative colitis
• Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carci … Ended
  2022-502078-17-00 4 2022-12-15 unresectable hepatocellular carcinoma
• A study to test trimodulin in adult hospitalized patients with CAP including COVID-19 pneumonia. Ended
  2024-513002-60-00 5 2022-10-26 Non-severe community-acquired pneumonia (CAP) or moderate or severe Co

Showing 97–120 of 130 trials